BTBD3: A Potential Drug Target for Inflammation and Fibrosis (G22903)

Target Name: BTBD3

NCBI ID: G22903

BTBD3

BTBD3: A Potential Drug Target for Inflammation and Fibrosis

BTBD3 (MGC130039) is a protein that is expressed in a variety of tissues, including the brain, heart, and kidneys. It is a member of the superfamily of transmembrane protein (SMP), which includes a group of proteins that are involved in various signaling pathways. BTBD3 has been shown to play a role in the regulation of inflammation and fibrosis, and is Therefore, it is a potential drug target (or biomarker) in the development of new therapeutic approaches for a variety of diseases.

BTBD3 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is characterized by a N-terminal 伪-helix and a C-terminal T-loop. The protein has a molecular weight of 62 kDa and a calculated pI of 6.3. BTBD3 is a member of the superfamily of transmembrane protein (SMP), which includes a group of proteins that are involved in various signaling pathways.

BTBD3 has been shown to play a role in the regulation of inflammation and fibrosis. For example, studies have shown that BTBD3 is involved in the regulation of neuroinflammation, and that it can protect against neuroinflammation in models of neurodegenerative diseases. Additionally, BTBD3 has been shown to play a role in the regulation of fibrosis, and that it can inhibit the activity of fibroblasts in models of fibrosis.

BTBD3 is also known as heat shock protein (HSP) 70, and it is a member of the HSP70 family. HSP70s are a group of proteins that are involved in various signaling pathways, including stress signaling pathways. BTBD3 has been shown to play a role in the regulation of stress responses, and that it can protect against stress-induced damage in cells.

In addition to its role in inflammation and fibrosis, BTBD3 is also known to play a role in the regulation of cell adhesion. Studies have shown that BTBD3 is involved in the regulation of cell-cell adhesion, and that it can affect the movement of cells along the body's surface.

BTBD3 is also a good candidate for a potential drug target (or biomarker) due to its unique structure and its involvement in various signaling pathways. Its role in the regulation of inflammation and fibrosis makes it a potential target for small molecules, antibodies, or other therapeutic agents that can modulate its activity. Additionally, its role in cell adhesion makes it a potential target for agents that can modulate its interactions with other cells.

In conclusion, BTBD3 is a protein that is expressed in a variety of tissues and is involved in various signaling pathways. Its role in the regulation of inflammation and fibrosis makes it a potential drug target (or biomarker) for the development of new therapeutic approaches for a variety of diseases. Further research is needed to fully understand the role of BTBD3 in the regulation of inflammation and fibrosis, and to develop effective therapeutic agents that can modulate its activity.

Protein Name: BTB Domain Containing 3

Functions: Acts as a key regulator of dendritic field orientation during development of sensory cortex. Also directs dendrites toward active axon terminals when ectopically expressed (By similarity)

The "BTBD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTBD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets